Selective Agonism of Liver and Gut FXR Prevents Cholestasis and Intestinal Atrophy in Parenterally Fed Neonatal Pigs.
選擇性激動肝臟和腸道 FXR 可防止靜脈營養餵養的新生豬膽汁淤積和腸道萎縮。
bioRxiv 2024-09-16
Farnesoid X receptor prevents neutrophil extracellular traps via reduced sphingosine-1-phosphate in chronic kidney disease.
Farnesoid X 受體透過降低慢性腎臟疾病中的鞘氨醇-1-磷酸酯,預防中性粒細胞外陷阱的形成。
Am J Physiol Renal Physiol 2024-02-27
Activation of farnesoid X receptor retards expansion of renal collecting duct cell-derived cysts via inhibition of CFTR-mediated Cl<sup>-</sup> secretion.
啟動法尼索酸X受體通過抑制CFTR介導的Cl-分泌,延緩腎集合管細胞源性囊腫擴展。
Am J Physiol Renal Physiol 2024-03-20
Evaluation of the Effects of Meal Type and Acid-Reducing Agents on the Pharmacokinetics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist.
評估餐型和降酸劑對選擇性非類固醇類類固醇類固醇X受體激動劑Cilofexor藥物動力學的影響。
Clin Pharmacol Drug Dev 2024-02-12
Animal studies on glucagon-like peptide-1 receptor agonists and related polyagonists in nonalcoholic fatty liver disease.
葡萄糖樣肽-1 受體激動劑及相關多激動劑在非酒精性脂肪肝病的動物研究。
Hormones (Athens) 2024-03-13
Glycodeoxycholic acid inhibits primary bile acid synthesis with minor effects on glucose- and lipid homeostasis in humans.
戊二醇胺膽酸抑制人體原生膽酸合成,對葡萄糖和脂質代謝影響較小。
J Clin Endocrinol Metab 2024-06-12
Inhibition of hepatic bile salt uptake by Bulevirtide reduces atherosclerosis in Oatp1a1<sup>-/-</sup>Ldlr<sup>-/-</sup> mice.
Bulevirtide抑制肝膽鹽攝取,降低Oatp1a1<sup>-/-</sup>Ldlr<sup>-/-</sup>小鼠的動脈粥樣硬化。
J Lipid Res 2024-07-15